The Current State of Personalized Medicine: Biomarkers in Pancreatic Cancer

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: June 06, 2018
Expiration Date: June 06, 2019

Expected time to complete this activity as designed: 15 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

The mainstay of pancreatic cancer therapy—cytotoxic regimens—have only minimally improved outcomes for this often-lethal malignancy, and targeted therapies have, to date, had only limited efficacy. This poor prognosis is a result of the late diagnosis of the disease, its early metastatic dissemination, the tumor’s immune privilege, the lack of robust drug targets in the tumor, and this cancer’s intrinsic resistance to systemic and immune therapies, in part owing to its abundant stromal content that creates a physical barrier to drug delivery. With better understanding of the genetic landscape of pancreas cancer, targeted approaches are emerging that will benefit biomarker-selected patients. New ways in which to enhance the microenvironment—both immunologically and to facilitate drug delivery—are also expected to result in better outcomes for patients.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including oncologists, pharmacists and other allied healthcare professionals who provide care to patients with pancreatic cancer.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Outline progress of a novel formulation of a naturally occurring enzyme (PEHPH20), currently being investigated as a potential biomarker-driven treatment for patients with advanced pancreatic cancer
  • Recognize pancreatic cancer patients who may benefit from an approved immunotherapeutic option (pembrolizumab) for patients with high MSI tumors


The Current State of Personalized Medicine: Biomarkers in Pancreatic Cancer – Eileen M. O’Reilly, MD

Instructions for Participation and Credit

This activity is eligible for credit through June 06, 2019. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Eileen M. O’Reilly, MD
Associate Director, Clinical Research
Rubenstein Center for Pancreatic Cancer Research
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York

Dr. Eileen M. O’Reilly received her medical degree at Trinity College (Dublin University) in her native Ireland. She completed her residency training in Ireland and her fellowship training at Memorial Sloan Kettering Cancer Center (MSKCC). Dr. O’Reilly serves as the Associate Director for Clinical Research at the David M. Rubenstein Center for Pancreatic Cancer Research at MSKCC, and is Professor of Medicine at Weill Cornell Medical College. In addition, she an Attending Physician, Gastrointestinal Oncology Services, at Memorial Hospital for Cancer and Allied Diseases in New York City.

Dr. O’Reilly is the co-chair of the NCI: Alliance Cooperative Group GI Committee and a member of numerous other professional organizations. She is the Principal Investigator of multiple trials in pancreas cancer and has authored/co-authored more than 200 articles, editorials and book chapters. An academic/translational investigator focused primarily on pancreas and hepatobiliary cancer with a broad interest in in all gastrointestinal malignancies, Dr. O’Reilly’s research initiatives include development of molecularly targeted therapy for pancreas cancer.


Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-18-010-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Eileen O’Reilly has received consultant fees from Agios; Amgen Inc.; Antengene Corporation; Aptus Pharma Pvt. Ltd.; ASLAN Pharmaceuticals; Astellas Pharma US, Inc.; AstraZeneca; Bayer AG; Boston Scientific Corporation; Bristol-Myers Squibb Company; CARsgen Therapeutics; CASI; Celgene Corporation; CytomX Therapeutics, Inc.; Daiichi Sankyo Company Limited; Debiopharm Group; Delcath Systems, Inc.; Eisai Co., Ltd.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd.; Gilead; Halozyme, Inc.; Inovio Pharmaceuticals, Inc.; Ipsen; Merck & Co., Inc.; Onxeo; PCI Biotech; Sanofi; SERVIER; Silenseed LTD; SillaJen Biotherapeutics; Sirtex; Vicus Therapeutics; and Yakult. She has received grant support related to research activities from Agios; Array BioPharma; AstraZeneca; Bayer; Bristol-Myers Squibb; CASI; Celgene; Exelixis; Eli Lilly; Incyte Corporation; F. Hoffmann-La Roche; Genentech, Inc.; Incyte Corporation, Inc.; MabVax Therapeutics Holdings, Inc.; MedImmune, LLC; Momenta Pharmaceuticals; Novartis; and OncoMed Pharmaceuticals, Inc.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Andrea Mathis, Project Manager, Keith D’Oria, Medical Writer, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.

©2018 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

MediCom Worldwide, Inc. would like to thank Celgene Corporation for their educational support of

©2020 MediCom Worldwide, Inc. All rights reserved